Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy.
Journal Information
Full Title: Urol Int
Abbreviation: Urol Int
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflict of Interest Statement R. Mizuno, MD, has received honoraria from Bristol, Ono, Merck, Takeda, and Pfizer. M. Oya, MD, has received honoraria from Bayer, Bristol, Novartis, Ono, Merck, Takeda, MSD, and Pfizer. Other authors declare that they have no conflict of interest."
Funding Disclosure
Evidence found in paper:
"Supported in part by grants-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan (20K09585 to R.M.)"
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025